Total
0
Shares
ResApp Health (ASX:RAP) - Managing Director & CEO, Tony Keating
Managing Director & CEO, Tony Keating
Source: Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ResApp Health (RAP) has teamed up with Australian-based telehealth company Doctors on Demand to integrate technologies
  • Under the initial one-year agreement, Doctors on Demand will integrate ResAppDx and SleepCheck into its online consultation offerings
  • Doctors on Demand provides both direct-to-consumer and business-to-business offerings, and its customers include Flight Centre, Allianz Partners and one of the world’s largest mining companies
  • On the market this morning, ResApp is up 4.44 per cent and is trading at 4.7 cents per share

ResApp Health (RAP) has signed a commercial agreement with Australian-based telehealth company Doctors on Demand.

The agreement will see Doctors on Demand integrate ResAppDx and SleepCheck into its online consultation offerings.

ResAppDx uses machine-learning technology to analyse cough sounds and diagnose respiratory diseases using just a smartphone’s built-in microphone.

SleepCheck is a sleep apnoea screening test that provides a risk of sleep apnoea based upon breathing and snoring sounds during sleep.

Doctors on Demand is one of Australia’s largest private telehealth businesses and provides both direct-to-consumer and business-to-business offerings. Its customers include Flight Centre, Allianz Partners and one of the world’s largest mining companies.

The parties have signed for an initial one-year partnership, with options to extend this for an additional year.

“We’re very pleased to have reached this innovative agreement,” CEO of Doctors on Demand Kirsty Garrett said.

“Our team are very excited to implement this impressive technology to support the highest standards of care in clinical practice for our respiratory patients wherever they are in Australia, whether that’s at a remote mine site in the Pilbara or student accommodation in Sydney. ”

ResApp CEO Dr Tony Keating is also pleased with the partnership.

“This partnership will allow us to grow our volume within our home market and importantly will provide us with real world data to support our evidence base for future reimbursement submissions for ResAppDx.”

On the market this morning, ResApp is up 4.44 per cent and is trading at 4.7 cents per share at 10:09 am AEST.

RAP by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.